Traditional antibody therapy has been limited to extracellular tumor targets; however, many oncogenic and tumor-associated proteins are intracellular. One strategy to overcome this limitation is to target the pHLA complex mimicking TCR recognition. In this webinar, Dr. W. Frank An will outline the current progress in the field of TCR-mimic (TCRm) antibody discovery, highlighting Biocytogen’s lead TCRm programs, which have generated highly specific antibodies for bispecific engager therapy and TCRm-T cell therapy.